The makers of Russia’s flagship Covid-19 vaccine said on Tuesday that interim results from phase 3 trials showed efficacy rates of “above 95 per cent”, overperforming some of the most effective of the western vaccines that have released results.
俄罗斯主要新型冠状病毒肺炎（COVID-19，即2019冠状病毒病）疫苗的生产商周二表示，第3期试验的中期结果显示，其有效率“高于95%”，超过一些已经发表结果的最有效的西方疫苗。
您已阅读6%（335字），剩余94%（5370字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。